A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
试验速览
- 阶段
- 不适用
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Left ventricular mass index
研究概览
简要总结
Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient medicine is available for acromegalic cardiomyopathy until now and there were limited studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients and independent of blood glucose control. We planed to evaluate the structure of heart by MRI before and after 6 months treatment with empagliflozin in acromegalic patients to investigate the effect of empagliflozin on acromegalic cardiomyopathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with pituitary GH adenomas confirmed by surgery
- •active acromegalic patients although treated with surgery,radiation therapy and somatostatin analogs
排除标准
- •patients with contraindications to empagliflozin pregnant patients patients with poor control of hypertension(SBP>150mmHg or DBP>95mmHg patients with contraindications to MRI
研究组 & 干预措施
empagliflozin
empagliflozin is added on the basis of the original treatment
干预措施: Empagliflozin (Drug)
结局指标
主要结局
Left ventricular mass index
时间窗: 6 months
the changes in left ventricular mass index by heart MRI
次要结局
未报告次要终点
研究者
Zhaoyun Zhang
vice director of endocrine department
Huashan Hospital